OSI Chronicles

OSI Chronicles

Shares of OSI Pharmaceuticals Inc. jumped 139% to an all-time high of $91.10 in April 2004 when Tarceva erlotinib met the primary endpoint in a Phase III trial in non-small cell lung cancer (NSCLC). Since then, the stock has traded between $25-$50, as the company faced a number of disappointments including failures associated with its acquisitions of Cell Pathways Inc. and Eyetech Pharmaceuticals Inc.Aptosyn exisulind

Read the full 665 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE